Naramig (Naratriptan)

Naratriptan works by stimulating serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve fibers. This causes the vessels to constrict and blocks the release of inflammatory neuropeptides, which together reduce the pain and other neurological symptoms of a migraine.

The specific dose of Naramig is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of naratriptan in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Naramig. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naramig (naratriptan) belongs to the triptan class, which is generally more specific for migraine relief than non‑specific analgesics such as NSAIDs. Compared with other triptans, naratriptan has a longer half‑life, which may provide sustained relief but can also be associated with a slightly higher incidence of certain side effects.

Naramig should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Naramig is taken orally, usually as a tablet, at the first sign of a migraine attack. It should be swallowed with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include chest pain or tightness that may indicate cardiac ischemia, serotonin syndrome when combined with other serotonergic agents, severe hypertension, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience any of these symptoms.

Naramig should be avoided in patients with uncontrolled hypertension, a history of coronary artery disease, stroke, or peripheral vascular disease, and in those taking MAO inhibitors, other triptans, or ergot derivatives. It is also contraindicated in individuals with known hypersensitivity to naratriptan or any of the tablet’s excipients.